Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
January 09, 2025 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
December 12, 2024 10:15 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
December 09, 2024 12:00 ET | Source: Aptose Biosciences, Inc.

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
August 24, 2023 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
August 10, 2023 16:02 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter 2023

─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
May 08, 2023 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the First Quarter 2023

─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet...
December 07, 2022 16:05 ET | Source: Aptose Biosciences, Inc.

Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...